ExpreS2ion Biotech Holding AB (publ) (STO:EXPRS2)

Sweden flag Sweden · Delayed Price · Currency is SEK
27.65
+0.65 (2.41%)
Jul 8, 2025, 5:23 PM CET
-42.40%
Market Cap 71.78M
Revenue (ttm) 9.22M
Net Income (ttm) -34.63M
Shares Out 2.66M
EPS (ttm) -17.02
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 7,202
Average Volume 11,064
Open 27.85
Previous Close 27.00
Day's Range 25.95 - 27.85
52-Week Range 15.74 - 66.56
Beta 1.95
RSI 62.06
Earnings Date Aug 21, 2025

About STO:EXPRS2

ExpreS2ion Biotech Holding AB (publ), a biotechnology company, develops vaccines and biologics products to address critical unmet medical needs in the Nordics and internationally. The company’s lead asset is ES2B-C001, a therapeutic vaccine which is in Phase 1 clinical trials for breast cancer that targets the human epidermal growth factor receptor 2. It is also developing ES2B-I002, a cytomegalovirus vaccine program to treat infectious diseases, as well as vaccines for Nipah virus, Malaria, and influenza. In addition, the company offers a huma... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2015
Employees 18
Stock Exchange Nasdaq Stockholm
Ticker Symbol EXPRS2
Full Company Profile

Financial Performance

In 2024, STO:EXPRS2's revenue was 7.83 million, a decrease of -11.07% compared to the previous year's 8.80 million. Losses were -36.04 million, -60.57% less than in 2023.

Financial Statements

News

There is no news available yet.